SCHEMBL498617

SCHEMBL498617

O=C(O)CS(=O)(=O)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.56
FPR1 P21462 1/20 0.56
MMP13 P45452 2/20 0.53
MMP12 P39900 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 1/20 0.53
TSHR P16473 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
MMP2 P08253 2/20 0.50
GLA P06280 1/20 0.50
FAAH O00519 1/20 0.50
PRSS1 P07477 1/20 0.50
PRSS2 P07478 1/20 0.50
ELANE P08246 1/20 0.50
PRTN3 P24158 1/20 0.50
PRSS3 P35030 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10338386 0.98 ALDH1A1 (0.54) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL2338220 0.83 CA2 (0.52) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL3929825 0.83 ALDH1A1 (0.58) ALDH1A1HSD17B10FPR1MMP13SMN1; SMN2
SCHEMBL581477 0.83 ALDH1A1 (0.57) ALDH1A1HSD17B10FPR1MMP13SMN1; SMN2
SCHEMBL1137128 0.82 LMNA (0.47) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL2337040 0.82 KMT2A (0.46) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL831127 0.82 KMT2A (0.51) MMP13MMP12SMN1; SMN2NPC1POLB
SCHEMBL3267907 0.82 KMT2A (0.69) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL2338295 0.82 KMT2A (0.46) ALDH1A1HSD17B10FPR1MMP13MMP12
SCHEMBL3237371 0.82 TSHR (0.56) ALDH1A1HSD17B10MMP13MMP12TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078296-A1 SUSTAINED-RELEASE SCALE INHIBITORS Materials Engineering and Technical Support Services (US) 2026-03-19 US claimed
WO-2024059615-A2 SUSTAINED-RELEASE SCALE INHIBITORS MATERIALS ENGINEERING AND TECHNICAL SUPPORT SERVICES CORPORATION (US) 2024-03-21 WO claimed
CN-112831173-B Composite material for automobile spoiler and preparation method thereof 无锡井上华光汽车部件有限公司 2021-10-15 CN claimed
CN-112831173-A Composite material for automobile spoiler and preparation method thereof 无锡井上华光汽车部件有限公司 2021-05-25 CN claimed
US-9090658-B2 Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2015-07-28 US claimed
EP-1664089-B1 BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF MEDICINES CO LEIPZIG GMBH (DE) 2011-11-16 EP claimed
US-20110264218-A1 INTERVERTEBRAL BODY IMPLANT, INSTRUMENT AND METHOD SPINECRAFT, LLC, A LIMITED LIABILITY COMPANY IN DELAWARE 2011-10-27 US claimed
EP-2292640-A2 Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof The Medicines Company (Leipzig) GmbH (DE) 2011-03-09 EP claimed
US-20070066539-A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2007-03-22 US claimed
EP-1664089-A1 BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF Curacyte Chemistry GmbH (DE) 2006-06-07 EP claimed
WO-2005026198-A1 BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF CURACYTE CHEMISTRY GMBH (DE) 2005-03-24 WO claimed
US-4637833-A OIL WELLS, GAS WELLS PHILLIPS PETROLEUM CO. (US) 1987-01-20 US claimed
JP-2078655-A None JP disclosed
US-20260078296-A1 SUSTAINED-RELEASE SCALE INHIBITORS Materials Engineering and Technical Support Services (US) 2026-03-19 US disclosed
EP-4182399-B1 ALKALINE EARTH METAL MINERALS AS CARRIERS FOR SURFACTANTS IN DRILLING FLUIDS OMYA INT AG (CH) 2025-09-03 EP disclosed
US-12319866-B2 Alkaline earth metal minerals as carriers for surfactants in drilling fluids OMYA INTERNATIONAL AG (CH) 2025-06-03 US disclosed
JP-H0278655-A PRODUCTION OF P-TOLUENESULFONYLACETIC ACID MITSUI TOATSU CHEM INC 1990-03-19 JP disclosed
US-4837316-A ANTIULCER AGENTS FUJIREBIO KABUSHIKI KAISHA (JP) 1989-06-06 US disclosed
US-4637833-A OIL WELLS, GAS WELLS PHILLIPS PETROLEUM CO. (US) 1987-01-20 US disclosed
US-4637833-A OIL WELLS, GAS WELLS PHILLIPS PETROLEUM CO. (US) 1987-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078296-A1 SUSTAINED-RELEASE SCALE INHIBITORS CEL, TST, CD44 ALDH1A1 1392/4885HSD17B10 349/4885FPR1 3905/4885
US-20070066539-A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof F12, F2, F11 ALDH1A1 690/4885HSD17B10 2025/4885FPR1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.